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Recent studies (1,  2) have indicated that endothelium provides a  focal point 
for the interaction of mechanisms inhibiting and promoting activation of coag- 
ulation. Perturbation of endothelium can induce procoagulant activity, allowing 
these cells to initiate and propagate an entire coagulation pathway leading to the 
deposition of fibrin (2). Thus, modulation of endothelial cell coagulant properties 
could play a role, comparable to the traditionally accepted leukocyte procoagu- 
lants, in promoting fibrin deposition in response to inflammatory and neoplastic 
stimuli. 
Prompted by this hypothesis and the recently described (3) identity between 
tumor necrosis factor (TNF) and cachectin, a  mediator of the host response in 
gram-negative sepsis (4), we have examined the effect of TNF on the coagulant 
properties  of endothelium.  The  results  indicate  that  cultured  bovine  aortic 
endothelial cells incubated with recombinant TNF have enhanced procoagulant 
activity, tissue factor, and concomitant suppression of the protein C pathway, an 
antithrombotic mechanism that functions on the surface of quiescent endothelial 
cells. This unidirectional shift in endothelial cell hemostatic properties promoting 
clot  formation  provides  insight  into  the  intercellular  signalling  by  which  a 
monokine generated in response to sepsis can modulate the role of endothelium 
in coagulation. 
Materials and Methods 
Cell Culture.  Bovine aortic and human umbilical vein endothelial cells were cultured 
and characterized as previously described (5). 
Treatment of Endothelial  Cells  with  TNF.  Experiments were carried out  24  h  after 
endothelial cells reached confluence using primary cultures and serially  passaged cells 
(passages  1-8).  Monolayers were washed three times with HBSS  (Gibco  Laboratories, 
Grand  Island,  NY),  serum-free  medium was  added along with TNF,  and  cells  were 
incubated for the indicated times at 37°C.  After the incubation period, cultures were 
washed three times with incubation buffer and assayed for tissue factor activity (9.6-cm 2 
wells), the ability to promote thrombin-mediated protein C activation (0.32-cm ~ wells), 
or the ability to promote activated protein C-protein S-mediated Factor Va inactivation 
(0.79-cm ~ wells). 
Reagents and Assays.  Recombinant human TNF, generously provided by BASF (Lud- 
wigshafen, Federal Republic of Germany), was used for all studies. This TNF preparation, 
which was free of detectable endotoxin at the concentrations used in these experiments, 
migrated as a single  band with an Mr of 17,000  under both reducing and nonreducing 
conditions on SDS-PAGE.  This material has identical properties to previously described 
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(6) preparations of TNF (a manuscript concerning the detailed characterization of this 
TNF is in preparation by BASF).  Heat treatment of TNF was carried out at 70°C for 1 
h, and resulted in loss of cytolytic activity and loss of its effect on endothelial cell coagulant 
parameters (Fig.  1). 
All coagulation factors were of bovine origin. The synthetic substrate tissue factor assay 
(Table I) (7) was carried out by adding purified Factors VIIa (8 nM) (generously provided 
by Dr. W. Kisiel,  University of New Mexico, Albuquerque, NM) and X (1.3 #M) (2) to 
monolayers in incubation buffer (1 ml) for 10 rain at 21 °C. Where indicated, rabbit anti- 
tissue factor IgG was added (200 ug/ml) (8) (generously provided by Dr. R. Bach, Mt. 
Sinai School of Medicine, New York) for 30 rain before the assay. One sample (0.1  ml) 
was removed from each reaction mixture and assayed for Factor Xa by monitoring (at 
405  nm)  hydrolysis of the  chromogenic substrate  benzo-Ile-Glu-Gly-Arg-p-nitroanilide 
(Helena Labs, Beaumont, TX) (0.1  ml; 0.05 nM) (2).  Factor Xa formation was linear, 
only limited by the amount of tissue factor. Tissue factor activity was also assessed  using 
a  one-stage coagulant  assay  as  previously described  (7).  The  amount  of tissue  factor 
present was determined by comparison of the clotting time with a standard curve using 
the same coagulant assay and purified bovine tissue  factor inserted into phospholipid 
vesicles (8) (generously provided by Dr. R. Bach). 
Thrombin-mediated protein C activation was studied, as described previously (9), by 
incubating samples with thrombin (0.1  U/ml) and protein C  (85 /~g/ml) for 40  min at 
37°C  in  incubation buffer (0.1  ml).  Antithrombin  III  (0.2  mg/ml) was  then added to 
neutralize residual thrombin, the reaction mixture was assayed for activated protein C by 
monitoring (at 405 nm) hydrolysis of the chromogenic substrate D-Phe-Pip-Arg-p-nitroan- 
ilide (Helena Labs; 0.05 ml; 2 mM). Activated protein C formation over endothelial cell 
monolayers was linear over the time of the assay. 
Protein S and Factor Va were purified to homogeneity as described (10).  Activated 
protein C-protein S-mediated  Factor Va inactivation was  studied by adding activated 
protein C  (1  nM),  protein  S (2  nM) and  Factor Va  (70 nM) for  1.5  min at  21°C  to 
monolayers in incubation buffer (0.5 ml). Samples were removed, one from each reaction 
mixture, and assayed for residual Factor Va activity using one-stage clotting assay (10). 
Rates  of Factor  Va  inactivation  were determined from  the  slope of the  linear initial 
portion of a plot of Factor Va activity versus incubation time. 
Results 
In contrast to the cytotoxic effect of TNF reported for tumor cells in vitro (3, 
6),  TNF  did  not  exert its  effect on  cultured  endothelial  cells  only via  direct 
cytotoxicity.  Rather,  TNF  specifically  modulated  endothelial  cell  hemostatic 
properties.  Tissue  factor,  a  cofactor initiating coagulation (8),  is  not normally 
expressed on the surface of endothelial cells. Incubation of cultured bovine aortic 
endothelial  cells  with  TNF  led  to a  dose-dependent induction  of tissue  factor 
(Fig. 1 A). The identity of this procoagulant activity as tissue factor was confirmed 
by the Factor VIIa-dependence of Factor X activation, which could be prevented 
by anti-tissue factor IgG (Table I). Although neoplastic tissue has been reported 
(11) to have a direct Factor X activating enzyme, TNF did not induce significant 
amounts of this activity in endothelium  (Fig.  1A, and Table I).  Destruction of 
TNF cytolytic activity by heat treatment also prevented the induction of endo- 
thelial  cell  tissue  factor,  indicating  a  requirement  for  the  functionally active 
molecule  (Fig.  1).  Similar  heat-treatment  of endotoxin  had  no  effect on  the 
induction of endothelial cell tissue factor (data not shown). Tissue factor activity 
induced by TNF was evident after a  2-h lag, increased steadily up to  10 h, and 
thereafter slowly declined (Fig.  1B). This is similar to the decay of IL-l-induced 
endothelial  cell  tissue  factor  activity  (12),  though  the  decline  appears  more 742  NAWROTH  AND  STERN 
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FIGURE  1.  Effect of TNF on endothelial cell hemostatic properties. Cultured bovine aortic 
endothelial cells were incubated with TNF and the effect on endothelial cell tissue factor (A, 
B), thrombin-mediated activated protein C formation (C, D) and activated protein C-protein 
S-mediated  Factor  Va  inactivation  (E,  F)  was  assessed. (A)  Dependence of tissue  factor 
induction on the dose of TNF. Monolayers were incubated with the indicated concentration 
of TNF (x) for 12 b. Tissue factor activity of endothelium was assessed by a coagulant assay 
as described in the text. Where indicated, Factor VII-deficient  plasma replaced normal plasma 
(A). Heat-treated TNF (0) or cycloheximide (2 ttg/ml) (0) were added to certain cultures. (B) 
Time course of tissue factor induction. Monolayers were incubated in  serum-free medium 
alone (A) or in the presence of TNF (10 nM) (X). Cycloheximide (0) or heat-treated TNF (O) 
was added where indicated. Tissue factor was assayed as described in Materials and Methods. 
Where indicated, Factor VII-deficient plasma was used (A).  (C)  Dependence of decreased 
thrombin-mediated  protein C activation.on the dose of TNF. Monolayers were incubated with 
the  indicated concentration of TNF  (×)  or  heat-treated TNF  (O). Endothelium was  then 
incubated with thrombin and protein C, as described in the text, to assess its ability to promote 
thrombin-mediated protein C activation. Where indicated, goat anti-rabbit thrombomodulin 
IgG  (150  #g/ml)  was preincubated with  endotbelium for  30  rain  (0).  Control  IgG  from 
nonimmune animals had no effect on the assay.  Results are expressed as activated protein C 
(APC) formed per 40  min per  l0  s cells.  (D).  Time course of decreased thrombin-mediated 
protein C activation. Monolayers were incubated with TNF (10 nM) (X), heat-inactivated TNF 
(O), or with serum-free medium alone (/~) for the indicated times, and washed. Where indicated, 
goat anti-rabbit thrombomodulin IgG (150 ~tg/ml)  (generously provided by Dr.  N.  Esmon, 
Oklahoma Medical Research Foundation) was preincubated with endothelium for 30 min (0). 
Endothelium was then incubated with thrombin and protein C  as described in the text to 
assess its ability to promote thrombin-mediated protein C activation. Results are expressed as 
activated protein C (APC) formed per 40  rain  per  10 n cells.  (E)  Dependence of decreased NAWROTH  AND  STERN  BRIEF  DEFINITIVE REPORT  743 
TABLE  I 
Activation  of Factor X by TNF-treated Endothelial Cells 
Factor Xa formed  Cell treatment  Assay reaction mixture  (pmol/108 cells) 
None  VIla, X  3 4- 1 
TNF  VIIa, X  108 4- 17 
TNF  X  4 4- 1 
TNF  VIla, X, anti-tissue factor lgG  114- 1 
Endothelial cell monolayers  were incubated with or without TNF (10 nM) for 12 h 
in serum-free medium and washed with incubation buffer. The tissue factor assay 
was then carried out using Factors Vlla and X as described in the text. Values are 
expressed as Factor Xa formed within I0 rain. 
gradual in the case of TNF.  Procoagulant activity on the endothelial  cell surface 
was  not  due  to  expression  from  a  preformed  pool,  since  lysates  of  control 
endothelial  cells  did  not  have  significant  tissue  factor  activity.  Furthermore, 
cycloheximide (2/zg/ml) blocked the induction of tissue factor by TNF, indicating 
a  requirement  for  de  novo  protein  synthesis  (Fig.  1B).  Thus,  TNF  induces 
endothelium to synthesize and express tissue factor. Similar results were observed 
with cultured human  umbilical vein endothelial  cells (data not shown). 
In view of the potent anticoagulant  mechanisms operative  on the endothelial 
cell  surface,  induction  of procoagulant  activity  may  not  be  sufficient  for  the 
vessel surface to play a  role in the pathogenesis of a  prethrombotic  state.  In this 
context,  the  importance  of endothelial  cell  participation  in  the  regulation  of 
coagulation is exemplified  by the thrombotic diathesis observed (13) in kindreds 
deficient in protein C  or protein S, since function of the protein C anticoagulant 
pathway  is  dependent  on  cofactors  present  on  the  endothelial  cell  surface. 
Endothelium  provides  both  a  cell  surface  protein,  thrombomodulin  (25),  en- 
hancing  thrombin-mediated  formation  of the  anticoagulant  enzyme-activated 
protein  C,  and  cofactor  activity  promoting  assembly  of activated  protein  C- 
protein  S  complex,  which is  the functionally effective anticoagulant  unit of the 
protein  C  pathway.  Activated protein  C  formation was in large part  dependent 
on  the  presence  of endothelial  cell  thrombomodulin,  as  indicated  by the  75% 
inhibition  of protein  C  activation  in  the  presence  of antithrombomodulin  IgG 
(Fig.  1 C).  TNF  resulted  in  a  dose-dependent  decrease  in  endothelial  cell- 
dependent  thrombin-mediated  protein  C  activation.  At a  TNF  concentration  of 
30  pM,  thrombomodulin-dependent  protein  C  activation  was  decreased  by 
~50%.  Decreased  activated  protein  C  formation  was  also  dependent  on  the 
activated  protein C-protein S-mediated Factor Va inactivation  on the dose of TNF. Mono- 
layers were incubated with the indicated  concentration of TNF (X) or heat-treated TNF (O) 
for 12 h. Endothelium was then assayed for the ability to promote activated protein C-protein 
S-mediated Factor Va inactivation  after incubation  with activated  protein C, protein S, and 
Factor Va, as described  in the text. Results are expressed as the rate of Factor Va inactivation 
per 105 cells. (F) Time course of decreased  activated  protein C-protein S-mediated Factor 
Va inactivation.  Monolayers were incubated with TNF (10 nM) (×), heat-inactivated  TNF (O), 
or with serum-free medium alone (A) for the indicated  times, and washed. Endothelium  was 
then assayed for the ability to promote activated  protein  C-protein S-mediated Factor Va 
inactivation  after the addition of activated  protein C, protein S, and Factor Va, as described 
in the text.  Results are expressed  as the rate of Factor Va inactivation per 105 cells. 744  NAWROTH  AND  STERN  BRIEF  DEFINITIVE  REPORT 
incubation  time of endothelium  with TNF,  with an effect evident by  1 h  and 
maximal  after  6  h  (Fig.  1D).  Controls  indicated  that  decreased  protein  C 
activation  was due  to decreased formation  of activated protein  C  rather  than 
inactivation of the thrombin added or the activated protein C formed. 
Recent  studies  (10)  have  shown  effective assembly  of functional  activated 
protein  C-protein  S complex on the endothelial  cell surface promoting  Factor 
Va inactivation,  and thereby regulating  thrombin  formation.  Activated protein 
C  is  the  enzyme  and  protein  S  functions  as  the  cell  surface cofactor (10).  In 
contrast to the rapid Factor Va inactivation observed with control monolayers, 
after incubation with TNF, the rate of Factor Va inactivation was reduced (Fig. 
1 E). This affect was half-maximal  at a TNF concentration  of 40 pM. The rate 
of Factory Va inactivation was attenuated in a time-dependent manner after the 
addition of TNF to cultures with negligible rates after 8 h (Fig.  1 F). 
Discussion 
The  results  reported  here  indicate  that  TNF  induces  endothelial  cell  tissue 
factor  while  suppressing  endothelial  cell-dependent  protein  C  activation  and 
anticoagulant  function on the cell surface.  Comparison  of the time course and 
dose-response  curve  for  TNF  modulation  of these  distinct  cellular  coagulant 
properties indicates  striking  similarities  in all  cases (Fig.  1).  This  suggests that 
expression of these hemostatic  properties may be under  coordinate control at 
the intracellular  level. Since a  concerted change  in the endothelial  cell surface 
promoting the activation of coagulation involves both anticoagulant and proco- 
agulant properties, such a linked control mechanism seems logical. The result of 
these changes is indicated by previous studies (2) showing that the induction of 
tissue factor in endothelial  cells initiates a procoagulant pathway leading to the 
deposition of fibrin.  Loss of effective function of the protein  C  anticoagulatnt 
pathway  further  enhances  the  propagation  of procoagulant  reactions  on  the 
endothelial cell surface. The net result of TNF-endothelial  cell interaction is a 
unidirectional shift in the balance of anticoagulant and procoagulant mechanisms 
on the endothelial  cell surface from the quiescent state in which anticoagulant 
mechanisms predominate,  to a stimulated state in which procoagulant activities 
are dominant. 
Fibrin  deposition  and  activation  of macrophages  around  malignant  tissues, 
potentially resulting in local TNF release, is commonly observed by pathologists. 
Furthermore,  the histologic description of the effect of TNF on tumors in vivo 
is often referred  to as hemorrhagic  necrosis.  This  leads to the hypothesis that 
local effects of TNF on endothelial  cell coagulant properties could result in a 
coagulopathy,  interrupting  normal  blood  flow  to  the  tumor  and  leading  to 
necrosis. This suggests a model in which monokines alter endothelial cell hemo- 
static properties promoting clot formation, potentially limiting pathologic proc- 
esses such as infection and tumors. 
Summary 
Tumor necrosis factor/cachectin (TNF) is a mediator of the septic state, which 
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previous  studies  have  shown  that  endothelial  cells  can  play an  active  role  in 
coagulation, we wished to determine whether TNF could modulate endothelial 
cell  hemostatic properties.  Incubation  of purified recombinant  TNF with cul- 
tured  endothelial  cells  resulted  in  a  time- and  dose-dependent  acquisition  of 
tissue  factor  procoagulant  activity.  Concomitant  with  enhanced  procoagulant 
activity, TNF also suppressed endothelial cell cofactor activity for the anticoag- 
ulant  protein  C  pathway;  both  thrombin-mediated  protein  C  activation  and 
formation of functional activated protein C-protein S complex on the cell surface 
were considerably attenuated. Comparable concentrations of TNF (half-maximal 
affect at ~50 pM) and incubation times (half-maximal affect by 4 h after addition 
to cultures) were required for each of these changes in endothelial cell coagulant 
properties. This unidirectional shift in cell surface hemostatic properties favoring 
promotion of clot formation indicates that, in addition to leukocyte procoagu- 
lants,  endothelium  can  potentially be  instrumental  in  the pathogenesis of the 
thrombotic state associated with inflammatory and malignant disorders. 
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